Creating value in the lives of the people we serve, now and into the future UCB is driven to ensure that everyone can live the best life they can, as free as possible from the challenges and uncertainty of a disease. This ambition fuels our purpose: creating value in the lives of the people we serve, now and into the future.Our research and development activity across neurology, immunology, and other areas where our expertise aligns with unmet needs is driven by our connection to the people we serve. Their unique and diverse perspectives serve as guides and inspiration as we explore the furthest reaches of science and medical knowledge UCB share price More in UCB Shares Consensus by Visible Alpha Financial & Extra Financial performance Equity Story Download Center Corporate Governance Shareholders Financial Guidance The figures of the guidance 2024 and 2025 as mentioned below were calculated on the same basis as the actual figures for 2023. 2024 Revenue€ 5.5 - 5.7 billionTaking into account the launches and the continued solid contributions from the existing product portfolio. 2024 adj. EBITDA 23.0% - 24.5%reflecting investments in launches around the globe to offer potential new solutions for people living with severe diseases and the commitment to invest into research and development to advance the late-stage and early development pipeline. 2024 Core EPS€ 3.70 - 4.40based on an average of 190 million shares outstanding 2025 Revenueat least € 6 billion 2025 adj. EBITDA Low- to mid-thirties (at the lower end of the range) 2025 Improved ESGrating performance Contact UCB IR Team investor-relations@ucb.com or a specific team member:Antje Witte, Head of Investor RelationsTel: +32 2 559 9414E-mail: Antje.Witte@ucb.com Sahar Yazdian, Investor Relations Lead Tel: +32 2 559 9137E-mail: Sahar.Yazdian@ucb.com Book a virtual meeting Send us feedback UCB IR App
